NodThera is a clinical stage biotechnology company developing a new class of medicines that inhibit the NLRP3 inflammasome to treat diseases driven by chronic inflammation.
NodThera is advancing NLRP3 inflammasome therapeutics through a novel drug discovery platform.
NodThera was founded in 2016 and is headquartered in Edinburgh, United Kingdom.
NodThera is leveraging new insights into inflammasome biology and chemistry to build a platform of highly differentiated small molecule NLRP3 inhibitors. NLRP3 is the core subunit of an inflammasome platform that allows the immune system to detect “danger signals,” including foreign molecules derived from pathogens and endogenous molecules associated with tissue damage or metabolic imbalances.
NodThera is backed by Novo Ventures, Cowen Healthcare Investments, Epidarex Capital, Sanofi Ventures, 5AM Ventures, F-Prime Capital, and Sofinnova Partners. The company raised $55M in Series B round on June 03, 2020. This brings NodThera's total funding to $95M to date.